Evidence map›Paper›PMID 39907835›Full record

ReviewMolecular biology reports2025

Plasmodium yoelii as a model for malaria: insights into pathogenesis, drug resistance, and vaccine development.

Oluwatobi Otun, Ikechukwu Achilonu

Abstract readReview
In one paragraph

Review in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Oluwatobi OtunProtein Structure-Function Unit, Department of Molecular and Cell Biology, University of Witwatersrand, Johannesburg, South Africa. oluwatobi.otun@wits.ac.za.
Ikechukwu AchilonuProtein Structure-Function Unit, Department of Molecular and Cell Biology, University of Witwatersrand, Johannesburg, South Africa.

Funding

National Research Foundation (NRF) of South Africa CPRR23042899244
6 · The paper itself

Abstract

Malaria continues to pose a serious global health threat, with rising drug resistance making treatment more difficult. Consequently, Plasmodium yoelii, a rodent malaria parasite, has become an invaluable model for studying the malaria parasite's complex biology, particularly host-parasite interactions and drug resistance mechanisms. Originating from African rodents, P. yoelii presents unique genetic diversity, mirroring critical aspects of human malaria and allowing for detailed research on the parasite's pre-erythrocytic and erythrocytic stages. This review introduces a novel perspective by comprehensively examining P. yoelii from multiple angles, including its origin, genetic composition, and contributions to vaccine development and drug efficacy studies. It highlights the significance of P. yoelii, revealing new insights into immune evasion, pathogenesis, and disease severity, which are critical for developing future malaria interventions. Furthermore, this review addresses the challenges associated with P. yoelii as a model, such as differences in host immune responses between rodents and humans. Despite these hurdles, the research using P. yoelii offers promising directions for combating malaria. This novel synthesis of P. yoelii studies underscores its essential role in advancing malaria research, particularly in understanding drug resistance and uncovering potential therapeutic and vaccine targets.

Indexed as

MalariaMalaria VaccinesPlasmodium yoeliiAnimalsAntimalarialsDisease Models, AnimalDrug ResistanceHost-Parasite InteractionsHumansVaccine DevelopmentAntimalarialsMalaria VaccinesDrug resistanceHost-parasite interactionsMalaria pathogenesisPlasmodium yoeliiVaccine development

Identifiers

PMID39907835
PMCPMC11799112

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.